| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-006 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 获得补助的 | 收到补助的时间 | | 补助 | 补助金额 | 是否与公司 日常经营活 | 是否已经 实际收到 | 是否具有 | | --- | --- | --- | --- | --- | --- | --- | --- | | 主体 | | | 形式 （元） | | | | 可持续性 | | | | | | | 动相关 | 款项 | | | 三诺生物 | 2025 年 1 月 23 日 | 现金 | | 29,615,015.44 | 是 | 是 | 是 | 二、补助的类型及其对上市公司的影响 1、补助的类型 根据《企业会计准则第 16 号——政府补助》的规定，与资产相关的政府补 助，是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益 相关的政府补助，是 ...

三诺生物传感股份有限公司 三诺生物传感股份有限公司 舆情管理制度 （2025 年 1 月） 第一章 总则 第一条 为提高三诺生物传感股份有限公司（以下简称"公司"）应对各类舆 情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司商业 信誉、正常生产经营活动以及投资价值等造成的影响，切实保护公司及利益相关 方合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证 券交易所创业板股票上市规则》等法律法规、规范性文件和《三诺生物传感股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，结合公司实际情况， 特制定本管理制度。 第二条 本管理制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道、不实报道； （二）社会上存在的已经或者将给公司造成不良影响的传言或信息； （三）可能或者已经影响公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第三条 公司应对各类舆情遵循"统一领导、统一组织、快速反应、协同应 对"基本原则，有效把握、引导舆论导向，避免和消除因媒体报道可能对公司造 成的各种负 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-004 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 二、会议审议情况 本次会议采用现场和通讯表决方式进行表决，经与会董事认真审议，本次会 议形成以下决议： （一）审议并通过《关于制定公司〈舆情管理制度〉的议案》 为提高公司应对各类舆情的能力，建立快速反应和应急处置机制，及时、妥 善处理各类舆情对公司商业信誉、正常生产经营活动以及投资价值等造成的影响， 切实保护公司及利益相关方合法权益，经与会董事审议，一致同意公司根据相关 法律法规、规范性文件和《公司章程》的有关规定，并结合公司实际情况，制定 《舆情管理制度》。 具体内容详见公司同日在中国证监会指定的创业板信息披露网站（巨潮资讯 网 www.cninfo.com.cn）上披露的《舆情管理制度》。 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届董事会第 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-001 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 1、三诺转债（债券代码：123090）转股期为2021年6月25日至2026年12月20 日；转股价格为人民币34.61元/股。 2、2024年第四季度，共有0张"三诺转债"完成转股（票面金额共计0元人 民币），合计转成0股"三诺生物"股票（股票代码：300298）。 3、截至2024年第四季度末，公司剩余可转债为4,984,224张，剩余可转债票 面总金额为498,422,400元人民币。 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司 自律监管指引第15号——可转换公司债券》的有关规定，三诺生物传感股份有限 公司（以下简称"公司"或"三诺生物"）现将2024年第四季度可转换公司债券 （以下简称"可转债"）转股及公司股份变动情况公告如下： 关于2024年第四季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重 ...

Investment Rating - Buy (Maintained Rating) [8][15] Core Views - The company's second-generation CGM (Continuous Glucose Monitoring) product has been approved domestically and is under FDA review, with catalysts both domestically and internationally expected to drive growth [5] - The second-generation CGM product features improved performance and user experience, utilizing third-generation direct electron transfer technology, which offers advantages such as low potential, oxygen independence, fewer interferences, better stability, and higher accuracy [5] - The product is designed for integration with Automated Insulin Delivery (AID) systems and targets the US market, which is the largest CGM market globally, with significant growth potential post-registration [4][14] - The company has secured a 7-year distribution agreement with a major European distributor, and both semi-automated and fully automated production lines are operational, positioning the company to capitalize on the global CGM market [6] Financial Performance and Projections - Revenue is projected to grow from 4,059 million RMB in 2023 to 5,928 million RMB in 2026, with a CAGR of 19% [7][10] - Net profit attributable to the parent company is expected to increase from 284 million RMB in 2023 to 635 million RMB in 2026, with a CAGR of 24% [7][10] - EPS is forecasted to rise from 0.50 RMB in 2023 to 1.13 RMB in 2026 [7][10] - The company's gross margin is expected to remain stable at around 54%, with net profit margin improving from 4.8% in 2023 to 11.0% in 2026 [10] Market and Industry Insights - The US CGM market is projected to grow from 2.7 billion USD in 2020 to 15.4 billion USD in 2030, with a CAGR of 19% [4] - The European CGM market is expected to expand from 1.2 billion USD in 2020 to 7.8 billion USD in 2030 [4] - The company's CGM product has received regulatory approval in China and is under FDA review in the US, with significant commercialization potential in the US market [13][14] Operational and Strategic Developments - The company has received regulatory approval for its CGM system in China, including an 8-day version for medical institutions and a 15-day version for home use [13] - The FDA has accepted the company's CGM product for substantive review, marking a key milestone in its US market entry [13] - The company has established both semi-automated and fully automated production lines, enhancing its capacity to meet global demand [6]

三诺生物传感股份有限公司（以下简称"公司"或"三诺生物"）于近日收 到湖南省药品监督管理局颁发的一项《中华人民共和国医疗器械注册证》，现将 具体情况公告如下： | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-090 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 二〇二四年十二月二十六日 | 序 | 产品名称 | 注册证编号 | 注册证 | 注册 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 号 | | | 有效期 | 分类 | | | 1 | 血糖尿酸血脂仪 | 湘械注准 20242221261 | 2024.12.09 | | 本产品与配套试条配合使用，用于定量检测 | | | | | | | 新鲜毛细血管全血、静脉全血和动脉全血中 | | | | | | | 的葡萄糖浓度，新鲜毛细血管全血、静脉全 | | | | | ...

该注册证的取得丰富了公司检测产品的品类和规格，有助于满足市场多元化的检测需求，进一步增强了 公司医疗器械产品的综合竞争力。 该产品与配套试条配合使用，用于定量检测新鲜毛细血管全血、静脉全血和动脉全血中的葡萄糖浓度， 新鲜毛细血管全血、静脉全血中的尿酸浓度，以及新鲜毛细血管全血中的总胆固醇浓度。 主要适用于糖代谢疾病、高尿酸血症和高胆固醇血症的辅助诊断，可供各级医疗机构中专业人员检测及 糖尿病患者、痛风患者、高尿酸血症患者、高胆固醇血症患者或其他人群进行自我监测。 财联社12月26日电，三诺生物公告，公司于近日收到湖南省药品监督管理局颁发的一项《中华人民共和 国医疗器械注册证》，产品名称为血糖尿酸血脂仪，注册证编号为湘械注准20242221261，有效期为 2024.12.09至2029.12.08，注册分类为II类。 但产品实际销售情况取决于未来市场推广效果，对上市公司未来经营业绩的影响存在不确定性。 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company has achieved significant milestones in its overseas market expansion, particularly with its Continuous Glucose Monitoring (CGM) system, which has received FDA acceptance and NMPA approval for various models [1][2] - The CGM product line is expected to see substantial sales growth, with projected revenues of 300 to 500 million yuan in 2024, following an estimated 80 million yuan in sales for 2023 [2] - The company has signed a distribution agreement with A.MENARINI DIAGNOSTICS S.r.l. for exclusive distribution in over 20 European countries, indicating strong international market penetration [1][3] Summary by Sections Product Development and Approval - The company’s CGM products have received necessary approvals, including FDA 510(k) acceptance and NMPA approval, with five models categorized for home and medical use [1] - The new generation of CGM products reflects the company's commitment to innovation and expanding its diabetes monitoring product line [2] Sales and Revenue Projections - The company anticipates a sales target of 300 to 500 million yuan for its CGM products in 2024, with profitability expected by 2025 [2] - The CGM industry is projected to experience accelerated growth, benefiting from the company's long-term investment in sensor technology since 2008 [2] International Expansion - The company has received CE certification for its CGM products and is poised for significant market penetration in Europe, with clinical trials in the U.S. progressing well [3] - The operational performance of overseas subsidiaries is improving, with expectations of profitability in the near term [3]

Investment Rating - The report maintains a "Buy" rating for the company, with a positive outlook on its future performance [5] Core Views - The company's Continuous Glucose Monitoring (CGM) products are expected to drive significant growth, with sales projected to reach 300-500 million yuan in 2024 and profitability anticipated by 2025 [2] - The company has achieved a milestone with its CGM products receiving FDA 510(k) acceptance and NMPA approval, further enhancing its product portfolio [1] - The company's international expansion is progressing well, with a distribution agreement signed for over 20 European countries and regions, and potential FDA approval in the US by 2025 [3] Financial Performance - Revenue is forecasted to grow from 2,814 million yuan in 2022 to 5,353 million yuan in 2026, with a CAGR of 19.15% to 10.77% [7] - Net profit is expected to increase from 431 million yuan in 2022 to 550 million yuan in 2026, with a CAGR of 300.56% to 27.70% [7] - ROE is projected to rise from 13.80% in 2022 to 13.89% in 2026, indicating improving profitability [7] Product Development - The company has launched new CGM models, including i6, i6s, i6Pro for home use (up to 15 days) and H6, h6 for medical institutions (up to 8 days) [1] - The company has been developing CGM products since 2008, with the latest generation approved in 2023, showcasing strong R&D capabilities [2] Market Expansion - The company has established a global sales network and brand resources, with significant potential for international market penetration, particularly in Europe and the US [3] - The company's overseas subsidiaries are expected to achieve profitability, marking a turning point in their operations [3] Valuation Metrics - The company's P/E ratio is expected to decrease from 36 in 2022 to 28 in 2026, indicating improving valuation attractiveness [7] - The P/B ratio is projected to decline from 5.0 in 2022 to 3.9 in 2026, reflecting potential undervaluation [7] Industry Outlook - The CGM industry is expected to experience accelerated growth, driven by the company's innovative products and expanding market presence [2] - The company's focus on diabetes monitoring and its diversified product line position it well to capitalize on market opportunities [2]

Investment Rating - The report maintains a "Buy" rating for Sanofi Bio [1] Core Views - Sanofi Bio has received formal notification from the U.S. FDA that its self-developed Continuous Glucose Monitoring (CGM) system has passed the acceptance review and has entered the substantive review phase, marking a significant step in its product registration process [2] - The approval signifies the quality and international competitiveness of the company's products, with a promising market potential in the U.S. CGM space, which is currently dominated by major players like Dexcom and Abbott [2] - The company has successfully completed the registration of its second-generation CGM product, showcasing its R&D capabilities and enhancing its product line to meet diverse market needs [3] - A partnership with A Menarini Diagnostics S.r.l. is expected to positively impact the company's business expansion in the European market [3] Financial Forecast and Valuation - The report maintains previous earnings forecasts, projecting revenues of 46.30 billion, 52.88 billion, and 60.93 billion yuan for 2024, 2025, and 2026 respectively, with corresponding net profits of 4.12 billion, 5.24 billion, and 6.22 billion yuan [4] - The current price-to-earnings (P/E) ratios are projected to be 38, 30, and 25 for the years 2024, 2025, and 2026 respectively, indicating the company's strong growth potential in the industry [4]